Continuous release of secretory granule proteoglycans from a cell strain derived from the bone marrow of a patient with diffuse cutaneous mastocytosis.
A human cell strain (designated HBM-M) that was derived from the bone marrow of a child with diffuse cutaneous mastocytosis was previously found to possess features that suggested it belonged in the mast cell/monocyte lineage. HBM-M cells synthesized approximately 150-Kd Pronase-resistant proteoglycans that were recognized by an antihuman secretory granule proteoglycan peptide core antibody. These cells also contained in relatively high abundance the same sized mRNA transcript that encodes the peptide core of proteoglycans that are normally localized to secretory granules of hematopoietic cells. However, unlike most other hematopoietic cells, HBM-M cells continuously released their newly synthesized 35S-labeled proteoglycans rather than retaining them in an intracellular storage compartment. Chondroitinase ABC, nitrous acid, and heparinase degraded approximately 76%, 17%, and 7%, respectively, of the HBM-M cell-derived 35S-labeled proteoglycans. As assessed by high performance liquid chromatography, 91% of the unsaturated 35S-labeled disaccharides generated by treatment with chondroitinase ABC were delta Di-4S. The remaining chondroitin sulfate 35S-labeled disaccharides appeared to be primarily a complex mixture of disulfated disaccharides. The 35S-labeled glycosaminoglycans that were not degraded by chondroitinase ABC migrated in two-dimensional cellulose acetate electrophoresis as if they were heparan sulfate or under-sulfated heparin. Thus, although the HBM-M cell-derived proteoglycans had some of the features of proteoglycans produced by normal human mast cells, the heparin-like and chondroitin sulfate glycosaminoglycans bound to the HBM-M cell proteoglycans were considerably less sulfated. Because the only human cell types that have so far been shown to synthesize proteoglycans that have heparin-like glycosaminoglycans bound to a protease-resistant peptide core are mast cells and basophilic leukocytes from patients with myelogenous leukemia, it is possible that the HBM-M cell is a mast cell progenitor cell.
Krilis
S A
SA
School of Medicine, University of New South Wales; Australia.
Austen
K F
KF
Macpherson
J L
JL
Nicodemus
C F
CF
Gurish
M F
MF
Stevens
R L
RL
D001853:Bone Marrow / Q000378:metabolism*; D002460:Cell Line; D002808:Chondroitin Lyases / Q000378:metabolism; D003594:Cytoplasmic Granules / Q000378:metabolism*; D004187:Disaccharides / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D006493:Heparin / Q000378:metabolism; D019763:Heparin Lyase; D006801:Humans; D007163:Immunosorbent Techniques; D009608:Nitrous Acid; D009693:Nucleic Acid Hybridization; D011133:Polysaccharide-Lyases / Q000378:metabolism; D011402:Pronase / Q000378:metabolism; D011509:Proteoglycans / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D013431:Sulfates / Q000378:metabolism; D014582:Urticaria Pigmentosa / Q000503:physiopathology*
D004187:Disaccharides; D006025:Glycosaminoglycans; D011509:Proteoglycans; D012333:RNA, Messenger; D013431:Sulfates; D006493:Heparin; D011402:Pronase; D002808:Chondroitin Lyases; D011133:Polysaccharide-Lyases; D019763:Heparin Lyase; D009608:Nitrous Acid